Table 2 Univariate and multivariate Cox proportional hazard regression analyses of CSS
From: Prognostic significance of the albumin-to-globulin ratio for upper tract urothelial carcinoma
Parameter | Cutoff | Univariate | Multivariate | ||
|---|---|---|---|---|---|
HR (95% CI) | P | HR (95% CI) | P | ||
Age at surgery | Continuous | 1.03 (0.99 to 1.07) per score | 0.07 | 1.03 (0.99 to 1.08) per score | 0.18 |
Sex | Male | Reference | < 0.05* | Reference | 0.14 |
Female | 2.15 (1.09 to 4.13) | 1.73 (0.83 to 3.51) | |||
Surgical technique | Open | Reference | 0.16 | Reference | 0.21 |
Laparoscopic | 0.50 (0.23 to 1.34) | 2.26 (0.63 to 8.93) | |||
Tumor location | Renal pelvis or both | Reference | 0.56 | Reference | 0.72 |
Ureter | 1.21 (0.63 to 2.33) | 1.14 (0.55 to 2.42) | |||
Tumor grade | G1/2 | Reference | < 0.01* | Reference | < 0.05* |
G3 | 4.10 (2.07 to 8.66) | 2.56 (1.07 to 6.50) | |||
Pathological T stage | ≤T2 | Reference | < 0.01* | Reference | 0.06 |
≥T3 | 3.67 (1.88 to 7.59) | 2.51 (0.96 to 6.70) | |||
Pathological N stage | N0/x | Reference | < 0.01* | Reference | 0.20 |
N1–3 | 4.82 (2.20 to 9.77) | 2.21 (0.65 to 7.00) | |||
Adjuvant chemotherapy | Yes | Reference | < 0.05* | Reference | 0.51 |
No | 0.49 (0.25 to 0.97) | 1.36 (0.55 to 3.37) | |||
Previous or synchronous bladder cancer | No | Reference | < 0.01* | Reference | < 0.01* |
Yes | 3.61 (1.83 to 6.92) | 3.49 (1.66 to 7.19) | |||
AGR | ≥1.25 | Reference | < 0.01* | Reference | < 0.01* |
< 1.25 | 3.90 (2.02 to 7.79) | 2.81 (1.34 to 6.10) | |||